Literature DB >> 32669323

Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.

Jan Wysocki1, Enrique Lores1, Minghao Ye1, Maria Jose Soler1,2, Daniel Batlle3.   

Abstract

Entities:  

Keywords:  ACE inhibitors; ACE2; COVID-19; angiotensin converting enzyme 2; angiotensin receptor blockers

Mesh：

Substances：

Year:  2020        PMID： 32669323      PMCID： PMC7461678          DOI： 10.1681/ASN.2020050667

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  10 in total

1.  Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

Authors:  Minghao Ye; Jan Wysocki; Josette William; Maria José Soler; Ivan Cokic; Daniel Batlle
Journal:  J Am Soc Nephrol       Date:  2006-10-04       Impact factor: 10.121

2.  Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.

Authors:  Carlos M Ferrario; Jewell Jessup; Mark C Chappell; David B Averill; K Bridget Brosnihan; E Ann Tallant; Debra I Diz; Patricia E Gallagher
Journal:  Circulation       Date:  2005-05-16       Impact factor: 29.690

3.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Authors:  Lei Fang; George Karakiulakis; Michael Roth
Journal:  Lancet Respir Med       Date:  2020-03-11       Impact factor: 30.700

4.  Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent.

Authors:  Peter Serfozo; Jan Wysocki; Gvantca Gulua; Arndt Schulze; Minghao Ye; Pan Liu; Jing Jin; Michael Bader; Timo Myöhänen; J Arturo García-Horsman; Daniel Batlle
Journal:  Hypertension       Date:  2019-12-02       Impact factor: 10.190

5.  Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan.

Authors:  María José Soler; Minghao Ye; Jan Wysocki; Josette William; Josep Lloveras; Daniel Batlle
Journal:  Am J Physiol Renal Physiol       Date:  2008-11-12

6.  SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.

Authors:  Carly G K Ziegler; Samuel J Allon; Sarah K Nyquist; Ian M Mbano; Vincent N Miao; Constantine N Tzouanas; Yuming Cao; Ashraf S Yousif; Julia Bals; Blake M Hauser; Jared Feldman; Christoph Muus; Marc H Wadsworth; Samuel W Kazer; Travis K Hughes; Benjamin Doran; G James Gatter; Marko Vukovic; Faith Taliaferro; Benjamin E Mead; Zhiru Guo; Jennifer P Wang; Delphine Gras; Magali Plaisant; Meshal Ansari; Ilias Angelidis; Heiko Adler; Jennifer M S Sucre; Chase J Taylor; Brian Lin; Avinash Waghray; Vanessa Mitsialis; Daniel F Dwyer; Kathleen M Buchheit; Joshua A Boyce; Nora A Barrett; Tanya M Laidlaw; Shaina L Carroll; Lucrezia Colonna; Victor Tkachev; Christopher W Peterson; Alison Yu; Hengqi Betty Zheng; Hannah P Gideon; Caylin G Winchell; Philana Ling Lin; Colin D Bingle; Scott B Snapper; Jonathan A Kropski; Fabian J Theis; Herbert B Schiller; Laure-Emmanuelle Zaragosi; Pascal Barbry; Alasdair Leslie; Hans-Peter Kiem; JoAnne L Flynn; Sarah M Fortune; Bonnie Berger; Robert W Finberg; Leslie S Kean; Manuel Garber; Aaron G Schmidt; Daniel Lingwood; Alex K Shalek; Jose Ordovas-Montanes
Journal:  Cell       Date:  2020-04-27       Impact factor: 41.582

7.  Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.

Authors:  Muthiah Vaduganathan; Orly Vardeny; Thomas Michel; John J V McMurray; Marc A Pfeffer; Scott D Solomon
Journal:  N Engl J Med       Date:  2020-03-30       Impact factor: 91.245

8.  Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.

Authors:  A H Jan Danser; Murray Epstein; Daniel Batlle
Journal:  Hypertension       Date:  2020-03-25       Impact factor: 10.190

9.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

10.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.

Authors:  I Hamming; W Timens; M L C Bulthuis; A T Lely; G J Navis; H van Goor
Journal:  J Pathol       Date:  2004-06       Impact factor: 7.996
  10 in total
  40 in total

Review 1.  Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices.

Authors:  Matthew A Sparks; Andrew M South; Andrew D Badley; Carissa M Baker-Smith; Daniel Batlle; Biykem Bozkurt; Roberto Cattaneo; Steven D Crowley; Louis J Dell'Italia; Andria L Ford; Kathy Griendling; Susan B Gurley; Scott E Kasner; Joseph A Murray; Karl A Nath; Marc A Pfeffer; Janani Rangaswami; W Robert Taylor; Vesna D Garovic
Journal:  Hypertension       Date:  2020-09-28       Impact factor: 10.190

2.  Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Single-Center Study.

Authors:  Alexandre Karras; Marine Livrozet; Hélène Lazareth; Nicolas Benichou; Jean-Sébastien Hulot; Antoine Fayol; Sophie Chauvet; Anne-Sophie Jannot; Marie-Aude Penet; Jean-Luc Diehl; Anne Godier; Olivier Sanchez; Tristan Mirault; Eric Thervet; Nicolas Pallet
Journal:  Clin J Am Soc Nephrol       Date:  2021-02-23       Impact factor: 8.237

3.  An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19.

Authors:  Charles D Bengtson; Robert N Montgomery; Usman Nazir; Lewis Satterwhite; Michael D Kim; Nathan C Bahr; Mario Castro; Nathalie Baumlin; Matthias Salathe
Journal:  Front Med (Lausanne)       Date:  2021-02-17

4.  Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.

Authors:  Jordana B Cohen; Thomas C Hanff; Vicente Corrales-Medina; Preethi William; Nicolas Renna; Nelson R Rosado-Santander; Juan E Rodriguez-Mori; Jonas Spaak; Jaime Andrade-Villanueva; Tara I Chang; Alejandro Barbagelata; Carlos E Alfonso; Eduardo Bernales-Salas; Johanna Coacalla; Carlos Augusto Castro-Callirgos; Karen E Tupayachi-Venero; Carola Medina; Renzo Valdivia; Mirko Villavicencio; Charles R Vasquez; Michael O Harhay; Jesse Chittams; Tiffany Sharkoski; James Brian Byrd; Daniel L Edmonston; Nancy Sweitzer; Julio A Chirinos
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-16       Impact factor: 3.738

5.  Renal involvement in patients with COVID-19.

Authors:  Márcia F Arantes; Camila E Rodrigues; Victor F Seabra; Paulo R G Lins; Bernardo V Reichert; Gabriel T M Sales; Igor Smolentzov; Carla P S Cabrera; Lúcia Andrade
Journal:  Clinics (Sao Paulo)       Date:  2020-10-26       Impact factor: 2.365

6.  Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.

Authors:  Axel Bauer; Michael Schreinlechner; Nikolay Sappler; Theresa Dolejsi; Herbert Tilg; Benedikt A Aulinger; Günter Weiss; Rosa Bellmann-Weiler; Christian Adolf; Dominik Wolf; Markus Pirklbauer; Ivo Graziadei; Hannes Gänzer; Christian von Bary; Andreas E May; Ewald Wöll; Wolfgang von Scheidt; Tienush Rassaf; Daniel Duerschmied; Christoph Brenner; Stefan Kääb; Bernhard Metzler; Michael Joannidis; Hans-Ulrich Kain; Norbert Kaiser; Robert Schwinger; Bernhard Witzenbichler; Hannes Alber; Florian Straube; Niels Hartmann; Stephan Achenbach; Michael von Bergwelt-Baildon; Lukas von Stülpnagel; Sebastian Schoenherr; Lukas Forer; Sabine Embacher-Aichhorn; Ulrich Mansmann; Konstantinos D Rizas; Steffen Massberg
Journal:  Lancet Respir Med       Date:  2021-06-11       Impact factor: 30.700

Review 7.  Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.

Authors:  Safaet Alam; Taslima Binte Kamal; Md Moklesur Rahman Sarker; Jin-Rong Zhou; S M Abdur Rahman; Isa Naina Mohamed
Journal:  Front Pharmacol       Date:  2021-06-14       Impact factor: 5.810

Review 8.  Pathophysiology of COVID-19-associated acute kidney injury.

Authors:  Matthieu Legrand; Samira Bell; Lui Forni; Michael Joannidis; Jay L Koyner; Kathleen Liu; Vincenzo Cantaluppi
Journal:  Nat Rev Nephrol       Date:  2021-07-05       Impact factor: 42.439

Review 9.  A Dual-Route Perspective of SARS-CoV-2 Infection: Lung- vs. Gut-specific Effects of ACE-2 Deficiency.

Authors:  Elizabeth M Sajdel-Sulkowska
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

10.  Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients.

Authors:  Ikram Omar Osman; Cléa Melenotte; Philippe Brouqui; Matthieu Million; Jean-Christophe Lagier; Philippe Parola; Andréas Stein; Bernard La Scola; Line Meddeb; Jean-Louis Mege; Didier Raoult; Christian A Devaux
Journal:  Front Immunol       Date:  2021-06-14       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.